High expression of insulin growth factor 2 mRNA binding protein 1 (IGF2BP1) is associated with a poor prognosis such as advanced clinical stage, increased tumor size, lymph node metastasis, and low survival rate of patients with HNSCC (69, 70). The gene discussed is IGF2BP1; the disease is metastatic malignant neoplasm in the lymph nodes.